PMID- 30429136
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Nov 14
TI  - SGLT2 inhibitors for diabetes are linked to increased risk of lower limb
      amputation.
PG  - k4828
LID - 10.1136/bmj.k4828 [doi]
FAU - Kmietowicz, Zosia
AU  - Kmietowicz Z
AD  - The BMJ.
LA  - eng
PT  - Journal Article
DEP - 20181114
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2018/11/16 06:00
MHDA- 2018/11/16 06:00
CRDT- 2018/11/16 06:00
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2018/11/16 06:00 [medline]
AID - 10.1136/bmj.k4828 [doi]
PST - epublish
SO  - BMJ. 2018 Nov 14;363:k4828. doi: 10.1136/bmj.k4828.

PMID- 30425041
OWN - NLM
STAT- In-Data-Review
LR  - 20190115
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 363
DP  - 2018 Nov 13
TI  - NHS England tells CCGs to end postcode lottery over diabetes glucose devices.
PG  - k4812
LID - 10.1136/bmj.k4812 [doi]
FAU - Iacobucci, Gareth
AU  - Iacobucci G
AD  - The BMJ.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - England
TA  - BMJ
JT  - BMJ (Clinical research ed.)
JID - 8900488
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - 10.1136/bmj.k4812 [doi]
PST - epublish
SO  - BMJ. 2018 Nov 13;363:k4812. doi: 10.1136/bmj.k4812.

PMID- 30426566
OWN - NLM
STAT- Publisher
LR  - 20181129
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Nov 13
TI  - Associations of dietary macronutrient and fibre intake with glycaemia in
      individuals with Type 1 diabetes.
LID - 10.1111/dme.13863 [doi]
AB  - AIMS: To study the association between dietary intake and glycaemia in Type 1
      diabetes. METHODS: Data on energy and nutrient intakes, and the mean and
      coefficient of variation of self-monitored blood glucose measurements were
      obtained from records completed by 1000 adults with Type 1 diabetes. Associations
      between these measures of glycaemia and dietary intake were investigated using
      generalized linear regression, with and without macronutrient substitution.
      RESULTS: In the first set of analyses, fibre intake was associated with lower
      mean self-monitored blood glucose values (beta = -0.428, 95% CI -0.624 to -0.231;
      P<0.001). In these same analyses, carbohydrate (beta = 0.011, 95% CI 0.002 to
      0.020; P=0.014), alcohol (beta = 0.013, 95% CI 0.003 to 0.023; P=0.009) and
      monounsaturated fatty acid intakes (beta=0.012, 95% CI 0.001 to 0.023; P=0.029)
      were associated with higher variability in blood glucose measurements. In the
      macronutrient substitution analyses, substituting proteins for either
      carbohydrates (beta = -0.026, 95% CI -0.040 to -0.013; P<0.001), fats (beta =
      -0.018, 95% CI -0.033 to -0.004; P=0.014), or alcohol (beta = -0.026, 95% CI
      -0.045 to -0.006; P=0.010), or fats for carbohydrates (beta=-0.009, 95% CI -0.017
      to -0.001; P=0.030), were all associated with lower variability in the measured
      blood glucose values. After adjusting for fibre intake, no significant results
      were observed in analyses of mean self-monitored blood glucose. CONCLUSIONS: This
      observational, cross-sectional study indicates that dietary fibre is associated
      with lower mean blood glucose concentrations in people with Type 1 diabetes.
      Glycaemic excursions were reduced when protein was substituted for other
      macronutrients and when fat replaced carbohydrate, after adjusting for fibre
      intake.
CI  - (c) 2018 Diabetes UK.
FAU - Ahola, A J
AU  - Ahola AJ
AUID- ORCID: https://orcid.org/0000-0001-5200-4597
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Helsinki, Finland.
AD  - Abdominal Centre Nephrology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
FAU - Harjutsalo, V
AU  - Harjutsalo V
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Helsinki, Finland.
AD  - Abdominal Centre Nephrology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
AD  - National Institute for Health and Welfare, Chronic Disease Prevention Unit,
      Helsinki, Finland.
FAU - Forsblom, C
AU  - Forsblom C
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Helsinki, Finland.
AD  - Abdominal Centre Nephrology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
FAU - Saraheimo, M
AU  - Saraheimo M
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Helsinki, Finland.
AD  - Abdominal Centre Nephrology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
FAU - Groop, P-H
AU  - Groop PH
AD  - Folkhalsan Institute of Genetics, Folkhalsan Research Centre, Helsinki, Finland.
AD  - Abdominal Centre Nephrology, University of Helsinki and Helsinki University
      Central Hospital, Helsinki, Finland.
AD  - Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki,
      Finland.
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Vic, Australia.
CN  - Finnish Diabetic Nephropathy Study
LA  - eng
GR  - Wilhelm and Else Stockmann Foundation
GR  - Diabetes Wellness Finland
GR  - Helsinki University Central Hospital Research Funds
GR  - The Liv och Halsa Foundation
GR  - Novo Nordisk Foundation
GR  - Suomen Akatemia
GR  - Folkhalsan Research Foundation
GR  - Signe ja Ane Gyllenbergin Saatio
PT  - Journal Article
DEP - 20181113
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/11/12 00:00 [accepted]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - 10.1111/dme.13863 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Nov 13. doi: 10.1111/dme.13863.

PMID- 30426553
OWN - NLM
STAT- Publisher
LR  - 20190103
IS  - 1464-5491 (Electronic)
IS  - 0742-3071 (Linking)
DP  - 2018 Nov 13
TI  - Carbohydrate restriction for glycaemic control in Type 2 diabetes: a systematic
      review and meta-analysis.
LID - 10.1111/dme.13862 [doi]
AB  - AIM: To conduct a systematic review and meta-analysis to evaluate the effect of
      carbohydrate restriction on glycaemic control in Type 2 diabetes. METHODS: We
      searched Medline, EMBASE and CINAHL for the period between 1976 and April 2018.
      We included randomized controlled trials comparing carbohydrate restriction with 
      a control diet which aimed to maintain or increase carbohydrate intake, and that 
      reported HbA1c as an outcome and reported the amount of carbohydrate consumed
      during or at the end of the study, with outcomes reported at >/=3 months.
      RESULTS: We identified 1402 randomized controlled trials, 25 of which met the
      inclusion criteria, incorporating 2132 participants for the main outcome.
      Definitions of low carbohydrate varied among the studies. The pooled effect
      estimate from meta-analysis was a weighted mean difference of -0.09% [95% CI
      -0.27, 0.08 (P = 0.30); I(2) 72% (P <0.001)], suggesting no effect on HbA1c of
      restricting the quantity of carbohydrate. A subgroup analysis of diets containing
      50-130 g carbohydrate resulted in a pooled effect estimate of -0.49% [95% CI
      -0.75, -0.23 (P <0.001); I(2) 0% (P = 0.56)], suggesting a clinically and
      statistically significant effect on HbA1c in favour of low-carbohydrate diets in 
      studies of </=6 months' duration. CONCLUSIONS: There was no overall pooled effect
      on HbA1c in favour of restricting carbohydrate; however, restriction of
      carbohydrate to 50-130 g per day had beneficial effects on HbA1c in trials up to 
      6 months. Future randomized controlled trials should be of >12 months' duration, 
      assess pre-study carbohydrate intake, use recognized definitions of
      low-carbohydrate diets and examine reasons for non-adherence to prescribed diets 
      in greater detail.
CI  - (c) 2018 Diabetes UK.
FAU - McArdle, P D
AU  - McArdle PD
AUID- ORCID: https://orcid.org/0000-0003-1096-5546
AD  - Birmingham Community Nutrition, Birmingham Community Healthcare NHS Foundation
      Trust, Birmingham, UK.
FAU - Greenfield, S M
AU  - Greenfield SM
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Rilstone, S K
AU  - Rilstone SK
AUID- ORCID: https://orcid.org/0000-0002-1671-3422
AD  - Imperial College Healthcare NHS Trust, London, UK.
FAU - Narendran, P
AU  - Narendran P
AUID- ORCID: https://orcid.org/0000-0002-4583-8793
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Haque, M S
AU  - Haque MS
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
FAU - Gill, P S
AU  - Gill PS
AUID- ORCID: https://orcid.org/0000-0001-8756-6813
AD  - Warwick Medical School, University of Warwick, Coventry, UK.
LA  - eng
GR  - National Institute for Health Research (NIHR)
GR  - Health Education England
GR  - Health Research and Care West Midlands
PT  - Journal Article
PT  - Review
DEP - 20181113
PL  - England
TA  - Diabet Med
JT  - Diabetic medicine : a journal of the British Diabetic Association
JID - 8500858
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/11/12 00:00 [accepted]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - 10.1111/dme.13862 [doi]
PST - aheadofprint
SO  - Diabet Med. 2018 Nov 13. doi: 10.1111/dme.13862.

PMID- 30425064
OWN - NLM
STAT- Publisher
LR  - 20181114
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Nov 13
TI  - The Familiality of Rapid Renal Decline in Diabetes.
LID - db180838 [pii]
LID - 10.2337/db18-0838 [doi]
AB  - Sustained and rapid loss of glomerular filtration rate (GFR) is the predominant
      clinical feature of diabetic kidney disease and a requisite for the development
      of end-stage renal disease. While GFR trajectories have been studied in several
      diabetic and non-diabetic cohorts, whether rapid renal decline clusters in
      diabetic families has not been examined. To determine this, we estimated GFR
      (eGFR) from serum creatinine measurements obtained from 15,612 patients with
      diabetes at the University of Utah Health Sciences Center and established their
      renal function trajectories. Patients with rapid renal decline (eGFR slope <-5
      ml/min/1.73m(2)/year) were then mapped to pedigrees using extensive genealogical 
      records from the Utah Population Database to identify high-risk rapid renal
      decline pedigrees. We identified 2,127 (13.6%) rapid decliners with a median eGFR
      slope of -8.0 mL/min/1.73m(2)/year and 51 high-risk pedigrees (ranging in size
      from 1,450-24,501 members) with excess clustering of rapid renal decline.
      Familial analysis showed that rapid renal decline aggregates in these families
      and is associated with its increased risk among first-degree relatives. Further
      study of these families is necessary to understand the magnitude of the influence
      of shared familial factors, including environmental and genetic factors, on rapid
      renal decline in diabetes.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Frodsham, Scott G
AU  - Frodsham SG
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah.
FAU - Yu, Zhe
AU  - Yu Z
AD  - Population Science, Huntsman Cancer Institute , University of Utah School of
      Medicine, Salt Lake City, Utah.
FAU - Lyons, Ann M
AU  - Lyons AM
AD  - Hospital Information Technology Services, Enterprise Data Warehouse, University
      of Utah Hospital and Clinics, Salt Lake City, Utah.
FAU - Agarwal, Adhish
AU  - Agarwal A
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah.
FAU - Pezzolesi, Melissa H
AU  - Pezzolesi MH
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah.
FAU - Dong, Li
AU  - Dong L
AD  - Division of Nephrology, Intermountain Healthcare, Salt Lake City, Utah.
FAU - Srinivas, Titte R
AU  - Srinivas TR
AD  - Division of Nephrology, Intermountain Healthcare, Salt Lake City, Utah.
FAU - Ying, Jian
AU  - Ying J
AD  - Department of Population Health Sciences, University of Utah School of Medicine, 
      Salt Lake City, Utah.
FAU - Greene, Tom
AU  - Greene T
AD  - Department of Population Health Sciences, University of Utah School of Medicine, 
      Salt Lake City, Utah.
FAU - Raphael, Kalani L
AU  - Raphael KL
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah.
AD  - Medicine Section and Research Section, Veterans Affairs Salt Lake City Health
      Care System, Salt Lake City, Utah.
FAU - Smith, Ken R
AU  - Smith KR
AD  - Population Science, Huntsman Cancer Institute , University of Utah School of
      Medicine, Salt Lake City, Utah.
FAU - Pezzolesi, Marcus G
AU  - Pezzolesi MG
AD  - Division of Nephrology and Hypertension, Department of Internal Medicine,
      University of Utah School of Medicine, Salt Lake City, Utah;
      marcus.pezzolesi@hsc.utah.edu.
AD  - Diabetes and Metabolism Center, University of Utah School of Medicine, Salt Lake 
      City, Utah.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/07/31 00:00 [received]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - db18-0838 [pii]
AID - 10.2337/db18-0838 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Nov 13. pii: db18-0838. doi: 10.2337/db18-0838.

PMID- 30425063
OWN - NLM
STAT- Publisher
LR  - 20181114
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Nov 13
TI  - NLRP3 Promotes Diabetic Bladder Dysfunction and Changes in Symptom-Specific
      Bladder Innervation.
LID - db180845 [pii]
LID - 10.2337/db18-0845 [doi]
AB  - The NLRP3 inflammasome senses diabetic metabolites and initiates inflammation
      implicated in diabetic complications and neurodegeneration. No studies have
      investigated NLRP3 in diabetic bladder dysfunction (DBD), despite a high clinical
      prevalence. In vitro, we found that numerous diabetic metabolites activate NLRP3 
      in primary urothelial cells. In vivo we demonstrate NLRP3 is activated in
      urothelia from a genetic Type 1 diabetic mouse (Akita) by week 15. We then bred a
      NLRP3(-/-) genotype into these mice and found this blocked bladder inflammation
      and cystometric markers of DBD. Analysis of bladder innervation established an
      NLRP3-dependent decrease in overall nerve density and Adelta-fibers in the
      bladder wall along with an increase in C-fiber populations in the urothelia,
      which potentially explains the decreased sense of bladder fullness reported by
      patients and overactivity detected early in DBD. Together, the results
      demonstrate the role of NLRP3 in the genesis of DBD and suggest specific
      NLRP3-mediated neuronal changes can produce specific DBD symptoms.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Hughes, Francis M Jr
AU  - Hughes FM Jr
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC. monty.hughes@duke.edu.
AD  - Department of Bioengineering. Clemson University. Clemson, SC.
FAU - Hirshman, Nathan A
AU  - Hirshman NA
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
FAU - Inouye, Brian M
AU  - Inouye BM
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
FAU - Jin, Huixia
AU  - Jin H
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
FAU - Stanton, Eloise W
AU  - Stanton EW
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
FAU - Yun, Chloe E
AU  - Yun CE
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
FAU - Davis, Leah G
AU  - Davis LG
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
AD  - Duke Cancer Center Biostatistics, Duke University Medical Center, Durham, NC.
FAU - Routh, Jonathan C
AU  - Routh JC
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
AD  - Department of Pediatrics, Duke University Medical Center, Durham, NC.
FAU - Purves, J Todd
AU  - Purves JT
AD  - Department of Surgery, Division of Urology, Duke University Medical Center,
      Durham, NC.
AD  - Department of Bioengineering. Clemson University. Clemson, SC.
AD  - Department of Pediatrics, Duke University Medical Center, Durham, NC.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/08/01 00:00 [received]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - db18-0845 [pii]
AID - 10.2337/db18-0845 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Nov 13. pii: db18-0845. doi: 10.2337/db18-0845.

PMID- 30425061
OWN - NLM
STAT- Publisher
LR  - 20181114
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Linking)
DP  - 2018 Nov 13
TI  - Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic
      Nephropathy.
LID - db180712 [pii]
LID - 10.2337/db18-0712 [doi]
AB  - Targeting Cell Division Autoantigen 1 (CDA1) is postulated to attenuate the
      profibrotic actions of transforming growth factor-beta in diabetic nephropathy.
      This study has identified a regulatory protein for CDA1 and has then used genetic
      and pharmacological approaches to test in vivo if strategies to target this
      pathway would lead to reduced renal injury. A novel protein, named CDA1BP1, was
      identified as critical in regulating the profibrotic activity of CDA1. Genetic
      deletion of CDA1BP1 attenuated key parameters of renal fibrosis in diabetic mice.
      Furthermore, a series of short synthetic CDA1BP1 peptides competitively inhibited
      CDA1-CDA1BP1 binding in vitro with a hybrid peptide, CHA-050, containing a 12mer 
      CDA1BP1 peptide and a previously known "Cell Penetrating Peptide",
      dose-dependently reducing expression of collagens I and III in HK-2 cells. In
      vivo, a D-amino acid retro-inverso peptide, CHA-061, significantly attenuated
      diabetes-associated increases in renal expression of genes involved in fibrotic
      and pro-inflammatory pathways. In a delayed intervention study, CHA-061 treatment
      reversed diabetes associated molecular and pathological changes within the
      kidney. Specifically, CHA-061 attenuated significantly renal extracellular matrix
      accumulation and glomerular injury. Taken together, targeting the CDA1/CDA1BP1
      axis is a safe, efficacious and feasible approach to retard experimental diabetic
      nephropathy.
CI  - (c) 2018 by the American Diabetes Association.
FAU - Chai, Zhonglin
AU  - Chai Z
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia; zhonglin.chai@monash.edu.
FAU - Wu, Tieqiao
AU  - Wu T
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia.
FAU - Dai, Aozhi
AU  - Dai A
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia.
FAU - Huynh, Pacific
AU  - Huynh P
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia.
FAU - Koentgen, Frank
AU  - Koentgen F
AD  - Ozgene Pty Ltd, Bentley, Western Australia, Australia.
FAU - Krippner, Guy
AU  - Krippner G
AD  - Department of Commercialization, Baker Heart and Diabetes Institute, Melbourne,
      Australia.
FAU - Ren, Shuting
AU  - Ren S
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia.
AD  - Department of Pathology, School of Basic Medical Sciences, Xi'an Jiaotong
      University Health Science Centre, Xi'an, China.
FAU - Cooper, Mark E
AU  - Cooper ME
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne,
      Australia.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/06/28 00:00 [received]
PHST- 2018/10/29 00:00 [accepted]
PHST- 2018/11/15 06:00 [entrez]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
AID - db18-0712 [pii]
AID - 10.2337/db18-0712 [doi]
PST - aheadofprint
SO  - Diabetes. 2018 Nov 13. pii: db18-0712. doi: 10.2337/db18-0712.

PMID- 30425094
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20190116
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Linking)
VI  - 41
IP  - 12
DP  - 2018 Dec
TI  - Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by
      the American Diabetes Association.
PG  - 2648-2668
LID - 10.2337/dci18-0052 [doi]
FAU - Arslanian, Silva
AU  - Arslanian S
AD  - Division of Pediatric Endocrinology, Metabolism, and Diabetes Mellitus,
      University of Pittsburgh, Pittsburgh, PA silva.arslanian@chp.edu.
AD  - Center for Pediatric Research in Obesity and Metabolism, UPMC Children's Hospital
      of Pittsburgh, Pittsburgh, PA.
FAU - Bacha, Fida
AU  - Bacha F
AUID- ORCID: 0000-0002-1528-9324
AD  - Children's Nutrition Research Center, Texas Children's Hospital and Baylor
      College of Medicine, Houston, TX.
FAU - Grey, Margaret
AU  - Grey M
AD  - Yale School of Nursing, New Haven, CT.
AD  - Yale School of Medicine, New Haven, CT.
FAU - Marcus, Marsha D
AU  - Marcus MD
AD  - University of Pittsburgh School of Medicine, Pittsburgh, PA.
FAU - White, Neil H
AU  - White NH
AD  - Washington University School of Medicine in St. Louis, St. Louis, MO.
FAU - Zeitler, Philip
AU  - Zeitler P
AD  - Children's Hospital Colorado and University of Colorado School of Medicine,
      Aurora, CO.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
EDAT- 2018/11/15 06:00
MHDA- 2018/11/15 06:01
CRDT- 2018/11/15 06:00
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2018/11/15 06:01 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - dci18-0052 [pii]
AID - 10.2337/dci18-0052 [doi]
PST - ppublish
SO  - Diabetes Care. 2018 Dec;41(12):2648-2668. doi: 10.2337/dci18-0052.

PMID- 30423132
OWN - NLM
STAT- Publisher
LR  - 20181113
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Nov 13
TI  - Plasma acylcarnitines and risk of type 2 diabetes in a Mediterranean population
      at high cardiovascular risk.
LID - 10.1210/jc.2018-01000 [doi]
AB  - Context: The potential associations between acylcarnitine profiles and incidence 
      of T2D, and whether acylcarnitines can be used to improve diabetes prediction
      remains unclear. Objective: To evaluate the associations between baseline and
      1-year changes in acylcarnitines, and their diabetes predictive ability beyond
      traditional risk factors. Design, setting and participants: We designed a
      case-cohort study within the PREDIMED Study including all incident cases of
      T2D(n=251) and 694 randomly selected participants at
      baseline(follow-up:3.8-years).Plasma acylcarnitines were measured using a
      targeted approach by liquid chromatography-tandem mass spectrometry(LC-MS).We
      tested the associations between baseline and 1-year changes in individual
      acylcarnitines and T2D risk using weighted Cox regression models.We used elastic 
      net regressions to select acylcarnitines for T2D prediction and compute a
      weighted score using a cross-validation approach. Results: An acylcarnitine
      profile, especially including short-chain and long-chain, was significantly
      associated with a higher risk of T2D independent of traditional risk factors.The 
      relative risk of T2D per SD increment of the predictive model scores were
      4.03(95%CI,3.00-5.42;P<0.001) for the conventional model, and
      4.85(95%,3.65-6.45;P<0.001) for the model including acylcarnitines, with a HR of 
      1.33 (95%CI,1.08-1.63;P<0.001) attributed to the acylcarnitines.Including the
      acylcarnitines into the model did not significantly improve the area under the
      receiver operator characteristic(ROC) curve (0.86 to 0.88,P=0.61).One-year
      increase in C4OH-carnitine was associated with higher risk of T2D[per SD
      increment: 1.44(1.03-2.01)]. Conclusions: An acylcarnitines profile, mainly
      including short- and long- chain acylcarnitines, was significantly associated
      with higher T2D risk in participants at high cardiovascular risk.The inclusion of
      acylcarnitines into the model did not significantly improve the T2D prediction
      c-statistics beyond traditional risk factors including fasting glucose.
FAU - Guasch-Ferre, Marta
AU  - Guasch-Ferre M
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
      USA.
AD  - Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili
      Health Research Institute, Rovira i Virgili University, Reus, Spain.
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
FAU - Ruiz-Canela, Miguel
AU  - Ruiz-Canela M
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - University of Navarra, Department of Preventive Medicine and Public Health,
      IDISNA (Health Research Institute of Navarra), Pamplona, Spain.
FAU - Li, Jun
AU  - Li J
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
      USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      MA, USA.
FAU - Zheng, Yan
AU  - Zheng Y
AD  - State Key Laboratory of Genetic Engineering and Ministry of Education Key
      Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan
      University, Shanghai, China.
FAU - Bullo, Monica
AU  - Bullo M
AD  - Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili
      Health Research Institute, Rovira i Virgili University, Reus, Spain.
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
FAU - Wang, Dong D
AU  - Wang DD
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
      USA.
FAU - Toledo, Estefania
AU  - Toledo E
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - University of Navarra, Department of Preventive Medicine and Public Health,
      IDISNA (Health Research Institute of Navarra), Pamplona, Spain.
FAU - Clish, Clary
AU  - Clish C
AD  - Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
FAU - Corella, Dolores
AU  - Corella D
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Department of Preventive Medicine, University of Valencia, Valencia, Spain.
FAU - Estruch, Ramon
AU  - Estruch R
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Department of Internal Medicine, Department of Endocrinology and Nutrition
      Biomedical Research Institute August Pi Sunyer (IDI- BAPS), Hospital Clinic,
      University of Barcelona, Barcelona, Spain.
FAU - Ros, Emilio
AU  - Ros E
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Lipid Clinic, Department of Endocrinology and Nutrition Biomedical Research
      Institute August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona,
      Barcelona, Spain.
FAU - Fito, Montserrat
AU  - Fito M
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Cardiovascular and Nutrition Research Group (Regicor Study Group), Hospital del
      Mar Research Institute (IMIM), Barcelona, Spain.
FAU - Aros, Fernando
AU  - Aros F
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Department of Cardiology, OSI ARABA. University Hospital, University of the
      Basque Country UPV/EHU. Vitoria-Gasteiz. Spain.
FAU - Fiol, Miquel
AU  - Fiol M
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Institute of Health Sciences IUNICS, University of Balearic Islands and Hospital 
      Son Espases, Palma de Mallorca, Spain.
FAU - Lapetra, Jose
AU  - Lapetra J
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Department of Family Medicine, Research Unit, Distrito Sanitario Atencion
      Primaria Sevilla, Sevilla, Spain.
FAU - Serra-Majem, Lluis
AU  - Serra-Majem L
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - Research Institute of Biomedical and Health Sciences (IUIBS), University of Las
      Palmas de Gran Canaria and Service of Preventive Medicine, Complejo Hospitalario 
      Universitario Insular Materno Infantil (CHUIMI), Canary Health Service, Las
      Palmas de Gran Canaria, Spain.
FAU - Liang, Liming
AU  - Liang L
AD  - Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston,
      MA, USA.
FAU - Papandreou, Christopher
AU  - Papandreou C
AD  - Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili
      Health Research Institute, Rovira i Virgili University, Reus, Spain.
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
FAU - Dennis, Courtney
AU  - Dennis C
AD  - Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
FAU - Martinez-Gonzalez, Miguel A
AU  - Martinez-Gonzalez MA
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
      USA.
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
AD  - University of Navarra, Department of Preventive Medicine and Public Health,
      IDISNA (Health Research Institute of Navarra), Pamplona, Spain.
FAU - Hu, Frank B
AU  - Hu FB
AD  - Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA,
      USA.
AD  - Channing Division of Network Medicine, Department of Medicine, Brigham and
      Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
AD  - Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston,
      MA, USA.
FAU - Salas-Salvado, Jordi
AU  - Salas-Salvado J
AD  - Human Nutrition Unit, Faculty of Medicine and Health Sciences, Pere Virgili
      Health Research Institute, Rovira i Virgili University, Reus, Spain.
AD  - CIBER de Fisiopatologia de la Obesidad y Nutricion (CIBEROBN), Instituto de Salud
      Carlos III, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20181113
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/11/14 06:00
MHDA- 2018/11/14 06:00
CRDT- 2018/11/14 06:00
PHST- 2018/05/08 00:00 [received]
PHST- 2018/11/08 00:00 [accepted]
PHST- 2018/11/14 06:00 [entrez]
PHST- 2018/11/14 06:00 [pubmed]
PHST- 2018/11/14 06:00 [medline]
AID - 5172268 [pii]
AID - 10.1210/jc.2018-01000 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Nov 13. pii: 5172268. doi: 10.1210/jc.2018-01000.

PMID- 30418614
OWN - NLM
STAT- Publisher
LR  - 20181112
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Nov 9
TI  - Association of plasma vitamin D metabolites with incident type 2 diabetes:
      EPIC-InterAct case-cohort study.
LID - 10.1210/jc.2018-01522 [doi]
AB  - Background: Existing evidence for the prospective association of vitamin D status
      with type 2 diabetes (T2D) is focused almost exclusively on circulating total
      25-hydroxyvitamin D [25(OH)D] without distinction between its subtypes:
      non-epimeric and epimeric 25(OH)D3 stereoisomers; and 25(OH)D2, the minor
      component of 25(OH)D. We aimed to investigate the prospective associations of
      circulating levels of the sum and each of these three metabolites with incident
      T2D. Methods: This analysis in the EPIC-InterAct case-cohort study for T2D
      included 9671 incident T2D cases and 13562 subcohort members. Plasma vitamin D
      metabolites were quantified by liquid-chromatography mass-spectrometry. We used
      multivariable Prentice-weighted Cox regression to estimate hazard ratios (HRs) of
      T2D for each metabolite. Analyses were performed separately within country, and
      estimates combined across countries using random-effects meta-analysis. Results: 
      The mean concentrations (standard deviation) of total 25(OH)D, non-epimeric
      25(OH)D3, epimeric 25(OH)D3 and 25(OH)D2 were 41.1 (17.2), 40.7 (17.3), 2.13
      (1.31), and 8.16 (6.52) nmol/L, respectively. Plasma total 25(OH)D and
      non-epimeric 25(OH)D3 were inversely associated with incident T2D
      [multivariable-adjusted HR per 1-SD=0.81 (95%CI: 0.77, 0.86) for both variables],
      while epimeric 25(OH)D3 was positively associated: per 1-SD HR=1.16 (1.09, 1.25).
      There was no statistically significant association with T2D for 25(OH)D2 [per
      1-SD HR=0.94 (0.76, 1.18)]. Conclusions: Plasma non-epimeric 25(OH)D3 was
      inversely associated with incident T2D, consistent with it being the major
      metabolite contributing to total 25(OH)D. The positive association of the
      epimeric form of 25(OH)D3 with incident T2D provides novel information to assess 
      the biological relevance of vitamin D epimerization and vitamin D subtypes in
      diabetes etiology.
FAU - Zheng, Ju-Sheng
AU  - Zheng JS
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
FAU - Imamura, Fumiaki
AU  - Imamura F
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
FAU - Sharp, Stephen J
AU  - Sharp SJ
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
FAU - van der Schouw, Yvonne T
AU  - van der Schouw YT
AD  - University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Sluijs, Ivonne
AU  - Sluijs I
AD  - University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
FAU - Gundersen, Thomas E
AU  - Gundersen TE
AD  - Vitas AS, Oslo, Norway.
FAU - Ardanaz, Eva
AU  - Ardanaz E
AD  - Navarra Public Health Institute, and IdiSNA, Navarra Institute for Health
      Research, Pamplona, Spain.
AD  - CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
FAU - Boeing, Heiner
AU  - Boeing H
AD  - Department of Epidemiology, German Institute of Human Nutrition
      Potsdam-Rehbruecke, Germany.
FAU - Bonet, Catalina
AU  - Bonet C
AD  - Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
FAU - Gomez, Jesus Humberto
AU  - Gomez JH
AD  - Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca,
      Murcia, Spain.
FAU - Dow, Courtney
AU  - Dow C
AD  - Inserm U1018, Center for Research in Epidemiology and Population Health (CESP),
      Paris-South Paris Saclay University, Gustave Roussy, Villejuif, France.
FAU - Fagherazzi, Guy
AU  - Fagherazzi G
AD  - Inserm U1018, Center for Research in Epidemiology and Population Health (CESP),
      Paris-South Paris Saclay University, Gustave Roussy, Villejuif, France.
FAU - Franks, Paul W
AU  - Franks PW
AD  - Department of Clinical Sciences, Lund University, Malmo, Sweden.
FAU - Jenab, Mazda
AU  - Jenab M
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Kuhn, Tilman
AU  - Kuhn T
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Kaaks, Rudolf
AU  - Kaaks R
AD  - Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
      Heidelberg, Germany.
FAU - Key, Timothy J
AU  - Key TJ
AD  - University of Oxford, UK.
FAU - Khaw, Kay-Tee
AU  - Khaw KT
AD  - Department of Public Health and Primary Care, University of Cambridge, Cambridge,
      UK.
FAU - Lasheras, Cristina
AU  - Lasheras C
AD  - Department of Functional Biology, Faculty of Medicine, University of Oviedo.
      Asturias, Spain.
FAU - Mokoroa, Olatz
AU  - Mokoroa O
AD  - CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
AD  - Public Health Division of Gipuzkoa, Biodonostia Research Institute, San
      Sebastian, Spain.
FAU - Mancini, Francesca Romana
AU  - Mancini FR
AD  - Inserm U1018, Center for Research in Epidemiology and Population Health (CESP),
      Paris-South Paris Saclay University, Gustave Roussy, Villejuif, France.
FAU - Nilsson, Peter M
AU  - Nilsson PM
AD  - Department of Clinical Sciences, Lund University, Malmo, Sweden.
FAU - Overvad, Kim
AU  - Overvad K
AD  - Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus,
      Denmark.
FAU - Panico, Salvatore
AU  - Panico S
AD  - Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples,
      Italy.
FAU - Palli, Domenico
AU  - Palli D
AD  - Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer
      Research, Prevention and Clinical Network - ISPRO, Florence, Italy.
FAU - Rolandsson, Olov
AU  - Rolandsson O
AD  - Umea University, Umea, Sweden.
FAU - Sieri, Sabina
AU  - Sieri S
AD  - Epidemiology and Prevention Unit, Milan, Italy.
FAU - Salamanca-Fernandez, Elena
AU  - Salamanca-Fernandez E
AD  - CIBER Epidemiology and Public Health CIBERESP, Madrid, Spain.
AD  - Escuela Andaluza de Salud Publica, Instituto de Investigacion Biosanitaria ibs
      and Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
FAU - Sacerdote, Carlotta
AU  - Sacerdote C
AD  - Unit of Cancer Epidemiology, Citta' della Salute e della Scienza
      Hospital-University of Turin and Center for Cancer Prevention (CPO), Torino,
      Italy.
FAU - Spijkerman, Annemieke Mw
AU  - Spijkerman AM
AD  - National Institute for Public Health and the Environment (RIVM), Bilthoven, The
      Netherlands.
FAU - Stepien, Magdalena
AU  - Stepien M
AD  - International Agency for Research on Cancer, Lyon, France.
FAU - Tjonneland, Anne
AU  - Tjonneland A
AD  - Danish Cancer Society Research Center, Copenhagen, Denmark.
FAU - Tumino, Rosario
AU  - Tumino R
AD  - ASP Ragusa, Italy.
FAU - Butterworth, Adam S
AU  - Butterworth AS
AD  - MRC/BHF Cardiovascular Epidemiology Unit and NIHR Blood and Transplant Research
      Unit in Donor Health and Genomics, Department of Public Health and Primary Care, 
      University of Cambridge, Cambridge, UK.
FAU - Riboli, Elio
AU  - Riboli E
AD  - School of Public Health, Imperial College London, London, UK.
FAU - Danesh, John
AU  - Danesh J
AD  - MRC/BHF Cardiovascular Epidemiology Unit and NIHR Blood and Transplant Research
      Unit in Donor Health and Genomics, Department of Public Health and Primary Care, 
      University of Cambridge, Cambridge, UK.
AD  - British Heart Foundation Cambridge Centre of Excellence, Division of
      Cardiovascular Medicine, Addenbrooke's Hospital, and Department of Human
      Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton,
      Cambridge, UK.
FAU - Langenberg, Claudia
AU  - Langenberg C
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
FAU - Forouhi, Nita G
AU  - Forouhi NG
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
FAU - Wareham, Nicholas J
AU  - Wareham NJ
AD  - MRC Epidemiology Unit, University of Cambridge, Cambridge, UK.
LA  - eng
PT  - Journal Article
DEP - 20181109
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/11/13 06:00
MHDA- 2018/11/13 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/07/12 00:00 [received]
PHST- 2018/11/06 00:00 [accepted]
PHST- 2018/11/13 06:00 [entrez]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2018/11/13 06:00 [medline]
AID - 5167366 [pii]
AID - 10.1210/jc.2018-01522 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Nov 9. pii: 5167366. doi: 10.1210/jc.2018-01522.

PMID- 30418583
OWN - NLM
STAT- Publisher
LR  - 20181112
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
DP  - 2018 Nov 9
TI  - Association Between Triglyceride Level and Glycemic Control Among Insulin-treated
      Patients With Type 2 Diabetes.
LID - 10.1210/jc.2018-01656 [doi]
AB  - Context: Elevated blood triglyceride levels are known to increase the risk of
      diabetes and prediabetes. However, it is still unclear whether elevated
      triglyceride levels are associated with inadequate glycemic control in type 2
      diabetic patients. Objective: To investigate the association between elevated
      triglyceride levels and inadequate glycemic control among insulin-treated
      patients with type 2 diabetes. Design, Setting, and Patients: We recruited 20,108
      type 2 diabetic patients who were treated with a sufficient dose of insulin.
      These patients were from the 2013 China National HbA1c Surveillance System study,
      which was a multi-center study conducted in Mainland China. Multivariate logistic
      regressions were used to assess the association of the triglyceride level with
      the inadequate glycemic control. Results: Overall, 56.0% of the included study
      subjects had elevated triglyceride levels (>/=1.70mmol/L), and prevalence of
      HbA1c >/=7.0% (53 mmol/mol) and >/=6.5% (48 mmol/mol) was 67.2% and 83.4%,
      respectively. The adjusted odds ratios of HbA1c >/=7.0% were 1.06 (0.98-1.15),
      1.35 (1.23-1.48) and 3.12 (2.76-3.53), respectively, for those with triglyceride 
      levels in ranges of 1.70-2.29, 2.30-3.39 and >/=3.40 mmol/L compared to those
      with triglyceride levels of <1.70 mmol/L. There was a similar association between
      triglyceride levels and HbA1c >/=6.5%. This positive association was confirmed by
      subgroup analyses among different subpopulations. There was also a strong
      nonlinear dose-response relationship between the triglyceride level and
      inadequate glycemic control. Conclusions: Elevated triglyceride levels were
      strongly associated with inadequate glycemic control, thus suppressing
      triglyceride levels might benefit in attaining a more optimal glycemic control in
      type 2 diabetic patients.
FAU - Zheng, Deqiang
AU  - Zheng D
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
FAU - Dou, Jingtao
AU  - Dou J
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
AD  - Department of Endocrinology, Hainan Branch of Chinese PLA General Hospital,
      Sanya, China.
FAU - Liu, Guangxu
AU  - Liu G
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
FAU - Pan, Yuesong
AU  - Pan Y
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
FAU - Yan, Yuxiang
AU  - Yan Y
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
FAU - Liu, Fen
AU  - Liu F
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
FAU - Gaisano, Herbert Y
AU  - Gaisano HY
AD  - Departments of Medicine and Physiology, University of Toronto, Toronto, ON,
      Canada.
FAU - Lu, Juming
AU  - Lu J
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
FAU - He, Yan
AU  - He Y
AD  - Department of Epidemiology and Health Statistics, School of Public Health,
      Capital Medical University, Beijing, China.
AD  - Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20181109
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
EDAT- 2018/11/13 06:00
MHDA- 2018/11/13 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/08/08 00:00 [received]
PHST- 2018/11/05 00:00 [accepted]
PHST- 2018/11/13 06:00 [entrez]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2018/11/13 06:00 [medline]
AID - 5167372 [pii]
AID - 10.1210/jc.2018-01656 [doi]
PST - aheadofprint
SO  - J Clin Endocrinol Metab. 2018 Nov 9. pii: 5167372. doi: 10.1210/jc.2018-01656.

PMID- 30424892
OWN - NLM
STAT- MEDLINE
DCOM- 20190114
LR  - 20190114
IS  - 1474-547X (Electronic)
IS  - 0140-6736 (Linking)
VI  - 393
IP  - 10166
DP  - 2019 Jan 5
TI  - SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal
      outcomes in type 2 diabetes: a systematic review and meta-analysis of
      cardiovascular outcome trials.
PG  - 31-39
LID - S0140-6736(18)32590-X [pii]
LID - 10.1016/S0140-6736(18)32590-X [doi]
AB  - BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors 
      (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity 
      is based on key baseline characteristics remains undefined. METHODS: We did a
      systematic review and meta-analysis of randomised, placebo-controlled,
      cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We
      searched PubMed and Embase for trials published up to Sept 24, 2018. Data search 
      and extraction were completed with a standardised data form and any discrepancies
      were resolved by consensus. Efficacy outcomes included major adverse
      cardiovascular events (myocardial infarction, stroke, or cardiovascular death),
      the composite of cardiovascular death or hospitalisation for heart failure, and
      progression of renal disease. Hazard ratios (HRs) with 95% CIs were pooled across
      trials, and efficacy outcomes were stratified by baseline presence of
      atherosclerotic cardiovascular disease, heart failure, and degree of renal
      function. FINDINGS: We included data from three identified trials and 34 322
      patients (60.2% with established atherosclerotic cardiovascular disease), with
      3342 major adverse cardiovascular events, 2028 cardiovascular deaths or
      hospitalisation sfor heart failure events, and 766 renal composite outcomes.
      SGLT2i reduced major adverse cardiovascular events by 11% (HR 0.89 [95% CI
      0.83-0.96], p=0.0014), with benefit only seen in patients with atherosclerotic
      cardiovascular disease (0.86 [0.80-0.93]) and not in those without (1.00
      [0.87-1.16], p for interaction=0.0501). SGLT2i reduced the risk of cardiovascular
      death or hospitalisation for heart failure by 23% (0.77 [0.71-0.84], p<0.0001),
      with a similar benefit in patients with and without atherosclerotic
      cardiovascular disease and with and without a history of heart failure. SGLT2i
      reduced the risk of progression of renal disease by 45% (0.55 [0.48-0.64],
      p<0.0001), with a similar benefit in those with and without atherosclerotic
      cardiovascular disease. The magnitude of benefit of SGLT2i varied with baseline
      renal function, with greater reductions in hospitalisations for heart failure (p 
      for interaction=0.0073) and lesser reductions in progression of renal disease (p 
      for interaction=0.0258) in patients with more severe kidney disease at baseline. 
      INTERPRETATION: SGLT2i have moderate benefits on atherosclerotic major adverse
      cardiovascular events that seem confined to patients with established
      atherosclerotic cardiovascular disease. However, they have robust benefits on
      reducing hospitalisation for heart failure and progression of renal disease
      regardless of existing atherosclerotic cardiovascular disease or a history of
      heart failure. FUNDING: None.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Zelniker, Thomas A
AU  - Zelniker TA
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Wiviott, Stephen D
AU  - Wiviott SD
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Raz, Itamar
AU  - Raz I
AD  - The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical
      Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem,
      Israel.
FAU - Im, Kyungah
AU  - Im K
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Goodrich, Erica L
AU  - Goodrich EL
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Bonaca, Marc P
AU  - Bonaca MP
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Mosenzon, Ofri
AU  - Mosenzon O
AD  - The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical
      Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem,
      Israel.
FAU - Kato, Eri T
AU  - Kato ET
AD  - Department of Cardiovascular Medicine, Kyoto University Graduate School of
      Medicine, Kyoto, Japan.
FAU - Cahn, Avivit
AU  - Cahn A
AD  - The Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical
      Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem,
      Israel.
FAU - Furtado, Remo H M
AU  - Furtado RHM
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA.
FAU - Leiter, Lawrence A
AU  - Leiter LA
AD  - Li Ka Shing Knowledge Institute, St Michael's Hospital, University of Toronto,
      Toronto, ON, Canada.
FAU - McGuire, Darren K
AU  - McGuire DK
AD  - Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, 
      TX, USA.
FAU - Wilding, John P H
AU  - Wilding JPH
AD  - Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
FAU - Sabatine, Marc S
AU  - Sabatine MS
AD  - TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, 
      MA, USA. Electronic address: msabatine@bwh.harvard.edu.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20181110
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - AIM
SB  - IM
CIN - Lancet. 2019 Jan 5;393(10166):3-5. PMID: 30424891
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Diabetic Nephropathies/etiology/*prevention & control
MH  - Humans
MH  - Primary Prevention/methods
MH  - Secondary Prevention/methods
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
EDAT- 2018/11/15 06:00
MHDA- 2019/01/15 06:00
CRDT- 2018/11/15 06:00
PHST- 2018/10/02 00:00 [received]
PHST- 2018/10/10 00:00 [revised]
PHST- 2018/10/11 00:00 [accepted]
PHST- 2018/11/15 06:00 [pubmed]
PHST- 2019/01/15 06:00 [medline]
PHST- 2018/11/15 06:00 [entrez]
AID - S0140-6736(18)32590-X [pii]
AID - 10.1016/S0140-6736(18)32590-X [doi]
PST - ppublish
SO  - Lancet. 2019 Jan 5;393(10166):31-39. doi: 10.1016/S0140-6736(18)32590-X. Epub
      2018 Nov 10.

PMID- 30415602
OWN - NLM
STAT- Publisher
LR  - 20181112
IS  - 1533-4406 (Electronic)
IS  - 0028-4793 (Linking)
DP  - 2018 Nov 10
TI  - Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
LID - 10.1056/NEJMoa1812389 [doi]
AB  - BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective
      inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients 
      with type 2 diabetes, is undefined. METHODS: We randomly assigned patients with
      type 2 diabetes who had or were at risk for atherosclerotic cardiovascular
      disease to receive either dapagliflozin or placebo. The primary safety outcome
      was a composite of major adverse cardiovascular events (MACE), defined as
      cardiovascular death, myocardial infarction, or ischemic stroke. The primary
      efficacy outcomes were MACE and a composite of cardiovascular death or
      hospitalization for heart failure. Secondary efficacy outcomes were a renal
      composite (>/=40% decrease in estimated glomerular filtration rate to <60 ml per 
      minute per 1.73 m(2) of body-surface area, new end-stage renal disease, or death 
      from renal or cardiovascular causes) and death from any cause. RESULTS: We
      evaluated 17,160 patients, including 10,186 without atherosclerotic
      cardiovascular disease, who were followed for a median of 4.2 years. In the
      primary safety outcome analysis, dapagliflozin met the prespecified criterion for
      noninferiority to placebo with respect to MACE (upper boundary of the 95%
      confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary
      efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in 
      the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95%
      CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death 
      or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 
      0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart
      failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group
      difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A 
      renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the
      placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any
      cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82
      to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with
      placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led
      to discontinuation of the regimen or that were considered to be serious adverse
      events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS: In patients with type 2 diabetes
      who had or were at risk for atherosclerotic cardiovascular disease, treatment
      with dapagliflozin did not result in a higher or lower rate of MACE than placebo 
      but did result in a lower rate of cardiovascular death or hospitalization for
      heart failure, a finding that reflects a lower rate of hospitalization for heart 
      failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number,
      NCT01730534 .).
FAU - Wiviott, Stephen D
AU  - Wiviott SD
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Raz, Itamar
AU  - Raz I
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Bonaca, Marc P
AU  - Bonaca MP
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Mosenzon, Ofri
AU  - Mosenzon O
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Kato, Eri T
AU  - Kato ET
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Cahn, Avivit
AU  - Cahn A
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Silverman, Michael G
AU  - Silverman MG
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Zelniker, Thomas A
AU  - Zelniker TA
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Kuder, Julia F
AU  - Kuder JF
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Murphy, Sabina A
AU  - Murphy SA
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Bhatt, Deepak L
AU  - Bhatt DL
AUID- ORCID: http://orcid.org/0000-0002-1278-6245
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Leiter, Lawrence A
AU  - Leiter LA
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - McGuire, Darren K
AU  - McGuire DK
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Wilding, John P H
AU  - Wilding JPH
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Ruff, Christian T
AU  - Ruff CT
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Gause-Nilsson, Ingrid A M
AU  - Gause-Nilsson IAM
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Fredriksson, Martin
AU  - Fredriksson M
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Johansson, Peter A
AU  - Johansson PA
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Langkilde, Anna-Maria
AU  - Langkilde AM
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
FAU - Sabatine, Marc S
AU  - Sabatine MS
AD  - From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of
      Cardiovascular Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z.,
      J.F.K., S.A.M., D.L.B., C.T.R., M.S.S.), and the Cardiology Division,
      Massachusetts General Hospital (M.G.S.) - both in Boston; the Diabetes Unit,
      Hadassah Hebrew University Hospital, Jerusalem (I.R., O.M., A.C.); the Department
      of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's Hospital,
      University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
      of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and
      Chronic Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.);
      and AstraZeneca Gothenburg, Molndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).
CN  - DECLARE-TIMI 58 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01730534
PT  - Journal Article
DEP - 20181110
PL  - United States
TA  - N Engl J Med
JT  - The New England journal of medicine
JID - 0255562
EDAT- 2018/11/13 06:00
MHDA- 2018/11/13 06:00
CRDT- 2018/11/13 06:00
PHST- 2018/11/13 06:00 [entrez]
PHST- 2018/11/13 06:00 [pubmed]
PHST- 2018/11/13 06:00 [medline]
AID - 10.1056/NEJMoa1812389 [doi]
PST - aheadofprint
SO  - N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389.